Anfield Capital Management LLC Takes Position in Boston Scientific Corporation $BSX

Anfield Capital Management LLC bought a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 23,525 shares of the medical equipment provider’s stock, valued at approximately $2,297,000.

A number of other hedge funds have also added to or reduced their stakes in the company. Brighton Jones LLC grew its position in Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares during the last quarter. Daymark Wealth Partners LLC boosted its stake in shares of Boston Scientific by 24.9% during the second quarter. Daymark Wealth Partners LLC now owns 4,820 shares of the medical equipment provider’s stock valued at $518,000 after purchasing an additional 961 shares in the last quarter. World Investment Advisors grew its holdings in shares of Boston Scientific by 31.7% during the second quarter. World Investment Advisors now owns 16,870 shares of the medical equipment provider’s stock worth $1,812,000 after purchasing an additional 4,061 shares during the last quarter. Arkadios Wealth Advisors increased its stake in shares of Boston Scientific by 8.4% in the second quarter. Arkadios Wealth Advisors now owns 20,740 shares of the medical equipment provider’s stock valued at $2,228,000 after buying an additional 1,606 shares during the period. Finally, Spire Wealth Management raised its holdings in Boston Scientific by 79.9% in the 2nd quarter. Spire Wealth Management now owns 19,128 shares of the medical equipment provider’s stock valued at $2,054,000 after buying an additional 8,498 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Insider Buying and Selling at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This represents a 10.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. The trade was a 42.32% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.50% of the company’s stock.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Street sentiment and recent analyst commentary lean favorable after the company’s quarterly results and guidance; the board added Cathy Smith and Christophe Weber, which investors view as governance/strategic strengthening. What Does the Street Think About Boston Scientific Corporation (BSX)?
• Positive Sentiment: Boston Scientific arranged multiple credit facilities totaling roughly $11 billion, boosting liquidity and providing financial flexibility for M&A, R&D, or share-repurchase plans — a constructive sign for risk management and capital strategy. Boston Scientific enters into multiple credit facilities totaling $11B
• Positive Sentiment: Management promoted an internal candidate to president of Vascular Therapies, signaling leadership continuity and succession depth in a key growth division. Boston Scientific promotes new president of Vascular Therapies from within
• Neutral Sentiment: Market coverage notes BSX is “trending” and trading up relative to the broader market on the session, driven partly by investor interest after earnings — useful for short-term flows but not a fundamental change. Boston Scientific (BSX) Ascends While Market Falls: Some Facts to Note
• Neutral Sentiment: Commentary points out BSX has trailed the Dow over recent periods despite analyst optimism — flags for investors focused on relative performance and timing for rotation into healthcare. Is Boston Scientific Stock Underperforming the Dow?
• Negative Sentiment: FDA-linked reporting: Boston Scientific halted use of certain AXIOS stent delivery devices after deployment issues associated with 167 injuries and three deaths — a material product-safety concern that can affect revenue, litigation exposure and reputation in the short-to-medium term. Boston Scientific Halts Use Of Select Stent Delivery Devices After Patient Deaths
• Negative Sentiment: An investor law firm (Pomerantz) has opened an investigation into claims on behalf of BSX investors, increasing legal risk and potential headline volatility. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation – BSX

Boston Scientific Stock Up 1.2%

Shares of NYSE:BSX opened at $76.68 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. Boston Scientific Corporation has a 52-week low of $72.69 and a 52-week high of $109.50. The business’s 50 day simple moving average is $87.31 and its two-hundred day simple moving average is $95.65. The firm has a market cap of $113.78 billion, a P/E ratio of 39.52, a PEG ratio of 1.05 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter in the previous year, the company posted $0.70 earnings per share. The company’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on BSX shares. Mizuho lowered their target price on Boston Scientific from $140.00 to $115.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Citigroup decreased their target price on shares of Boston Scientific from $130.00 to $102.00 and set a “buy” rating for the company in a research report on Thursday, February 5th. Truist Financial dropped their price target on shares of Boston Scientific from $120.00 to $95.00 and set a “buy” rating on the stock in a research report on Thursday, February 5th. Finally, Robert W. Baird reduced their price objective on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $108.36.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.